All that pumping and they only managed to raise just over £1m! Just goes to show what little interest there is in the company! |
So they released a pump RNS a few weeks ago, to help get a placing away this week.Classic.Lemmings and mushrooms only. |
Yes supernumerary. The stream of positive newsflow back in 2016-2018 carried the shares from around 25p to 180p. That is what holders are expecting. Old lollywally continues to hold the shares he bought at 7p+ a few years ago presumably because he also anticipates a positive stream of newsflow. Or perhaps he doesn't? All we know about lollywally is that when the shares fall he likes to bash other people, and when the shares rise he gives himself a pat on the back. He is little more than a pointless commentator, I'm afraid. |
supernumerary - I'm assuming your post was sarcastic, seeing as only one of the past six Lanstead deals actually resulted in gains for IMM.
And that was back in 2016 when the share price was riding relatively high in the build up to the first (failed) P3 trial. |
wiggy - you're right - McCarthy is a past master at getting the best out of these Lanstead deals, which requires a constant news flow to keep the share price buoyant. If he can pull the trick off again, there's certainly a potential for trading profits, but I retain doubts about the longer term. |
Nobby - quite :¬) The world isn't standing still - even if they do eventually get through the trial successfully, there'll be an awful lot more competition around, which will be supported by companies with much deeper pockets.
McCarthy's doing a great job keeping this alive, but not so well at advancing the drug. |
There may be interim results, there may be partnership news, there may be upfront payments... there may be all kinds of lovely things over the next couple of years. GLA |
The point being we are unlikely to get the final results from the Avion trial until 2028 now. Yes I know there will be some interim results concerning the dose level along the way but the fund raise today is essentially due to these extended delays |
But Super, Avion still haven’t commenced the phase 2/3 trial in lupus with the new (much higher) dose. That will be the only real saviour of the company assuming it’s positive. Yes Tim may cobble together some other deal but I doubt the terms will be very appealing. After all Avion paid zero upfront which is very unusual in the Pharma world!
This remains a desperate company…. |
 It's good to see money pouring into lupus research. I guess you all saw this:
Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program
Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of assets with potential peak sales of $14 billion.
The candidate, the anti-BDCA2 antibody litifilimab, is in phase 3 development in systemic and cutaneous lupus erythematosus (SLE/CLE). There is unmet need in both diseases. SLE patients have limited choices, with GSK’s Benlysta and AstraZeneca’s Saphnelo the only options, but that is rich pickings compared to CLE. Physicians have been waiting decades for an advance in the treatment of the cutaneous disease.
Biogen believes litifilimab can address the unmet needs. But, with a pipeline of other programs—including two other lupus assets—to develop, the biotech has opted to seek external money to fund phase 3 trials in SLE and CLE.
[...] |
Not a kick in the teeth at all, nob. Placing price is at around a 100% premium to where I bought my shares, and ensures funding for 18months+. Relatively small dilution circa 10%. If you don't use a lot of cash, you don't need a lot of cash. Well done Tim :) |
are in any share price appreciation over the Benchmark Price (as defined below). However, if the Company's share price is less than the Benchmark Price then the amount received by the Company under the Sharing Agreement will be less than the gross proceeds of the Lanstead Subscription which were pledged by the Company to Lanstead at the outset. |
Another kick in the teeth for shareholders as Tim ensures his pay for another year or so. And when is that phase 2/3 trial going to start….
Looks like the pump is well and truly over and here comes an almighty dump! |
will be back to 7p in a day or two |
This is a dog! |
this is now taking off |
No doubt Lanstead are going to sell their 2p shares aaaaall the way down then leave the trough |
Time for top up |
Market makers are short not punters |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
